Reusable 3D-printing ink shows promise for gabapentin tablets: full analysis

A new proof-of-concept study suggests veterinary clinics and pharmacies may be able to reuse some gelatin-based 3D printing inks to make personalized gabapentin tablets on demand, potentially cutting waste and reducing prep burden. In Frontiers in Veterinary Science, investigators from institutions in Finland and Sweden tested reusable formulations for semi-solid extrusion printing and found that a lower-concentration gabapentin ink remained printable and dose-accurate after 14 days of refrigerated storage, while a higher-concentration version became unstable and formed crystals. (frontiersin.org)

The work builds on a growing body of research around 3D-printed veterinary medicines, particularly for patients that need individualized doses that don’t map neatly onto commercially available products. Gabapentin is a useful example because it is widely used in veterinary medicine for anxiety, pain, and epilepsy, yet tailored dosing can be difficult in small patients. Earlier research published in 2022 showed that semi-solid extrusion 3D printing could produce gabapentin-containing chewable tablets for veterinary use, and noted that marketed veterinary gabapentin products were limited, pushing clinicians toward compounding or off-label use of human products. (frontiersin.org)

In the new study, the researchers used CuraVet®, described as an already available proprietary gelatin-based excipient base, to prepare two gabapentin formulations with different drug concentrations. Each formulation was printed once, then printed again from the same syringe after 14 days in refrigerated storage. The lower-concentration formulation maintained printability and dosing precision without requiring printer-setting changes, and the team reported that chewable tablets could be produced in less than 30 minutes with minimal active labor. The higher-concentration formulation, by contrast, showed crystal formation, an indicator that reusability may depend heavily on drug load and formulation stability rather than on the printing platform alone. (frontiersin.org)

That stability point is consistent with broader pharmaceutical 3D-printing research. A 2025 pilot study on veterinary pimobendan printlets found that real-world implementation depends on whether inks remain stable during storage and repeated use, and argued that placebo-base stability alone may not predict the behavior of the final drug-loaded product. Other reviews and expert papers have made a similar point: the promise of personalized, on-demand printing is real, but routine adoption will require practical quality assurance, reproducibility testing, and workflow standards that fit clinic and pharmacy settings. (sciencedirect.com)

Direct outside commentary on this specific gabapentin paper was limited at the time of writing, but the broader industry view is fairly consistent. Reviews on pharmaceutical 3D printing describe the technology as a strong fit for precision compounding, especially where conventional dosage strengths are a poor match for individual patients. At the same time, regulatory and hospital-pharmacy experts continue to flag unresolved questions around classification, quality control, feedstock handling, and how 3D-printed medicines should be governed when they sit somewhere between traditional compounding and manufacturing. (mdpi.com)

Why it matters: For veterinary professionals, this study is less about gabapentin alone and more about operational feasibility. If reusable inks can be stored and reprinted without losing dose accuracy, point-of-care production of tailored tablets becomes more realistic for small animal patients that need individualized strengths or easier-to-administer dosage forms. That could improve precision and reduce discarded material, but the study also underscores the limits: not every formulation will remain stable, and concentration-dependent crystallization could affect both dose reliability and product performance. In practice, clinics, compounding pharmacies, and hospital services would still need validated storage windows, formulation-specific QC checks, and clear protocols before using a reusable-print approach clinically. (frontiersin.org)

What to watch: The key questions now are whether the findings hold across longer storage periods, other active ingredients, and larger production runs, and whether regulators or professional pharmacy groups move toward more explicit guidance for 3D-printed personalized medicines. Until then, the technology looks promising as a sustainability and workflow advance, but still sits in an early translational phase rather than routine veterinary practice. (sciencedirect.com)